Intuitive Surgical stock stabilizes after sharp 2026 pullback as new cardiac use expands da Vinci 5
Published on 08/18/2026 at 17:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Intuitive Surgical Inc. (US46120E6023) stock has retreated to the high-$390 range as of August 17, 2026, leaving the robotic-surgery pioneer more than 30 percent below its level at the start of the year even as procedure volumes continue to grow in double digits.
Per recent market data as of August 17, 2026, Intuitive Surgical shares closed at $390.33 on the Nasdaq, down 31.1 percent year to date from $566.36, underscoring the extent of the 2026 drawdown despite ongoing operational expansion in its da Vinci franchise.
This marks a sharp reset in valuation for a company whose stock has historically compounded in the mid-teens annually, creating a different entry and risk profile for investors assessing the balance between competition, regulatory momentum, and long-term procedure growth.
Shares pull back but procedure growth holds
Market data compiled on August 18, 2026 show Intuitive Surgical trading around $390 per share, with recent closes reported between $390.24 and $394.51, reflecting modest day-to-day volatility but a clear step down from early-2026 levels above $560.
According to a detailed stock overview, Intuitive Surgical shares closed at $390.33 on August 17, 2026, representing a decrease of 31.1 percent from $566.36 at the beginning of 2026, a quantified decline that highlights how sentiment toward medtech and surgical devices has reset over the past months.
Another market summary notes Intuitive Surgical closing August 14, 2026 at $394.51, roughly 20 percent above a 52-week low of $328.57, indicating that while the stock has fallen significantly year to date, it is no longer trading at the absolute troughs seen earlier in the year.
This positioning - down more than 30 percent for 2026 yet around 20 percent above the 52-week low - gives investors a clearer sense of both the downside that has already occurred and the remaining gap back to prior valuation peaks.
For context, one performance overview points out that Intuitive Surgical stock has averaged annual gains of 17 percent over the past decade, reinforcing how the current year’s decline stands out against a long-run trend of steady appreciation.
The company’s shares also show shorter-term moves, with intraday snapshots on August 18, 2026 indicating prices in the high-$390 range and small positive or negative changes of roughly 1 percent, consistent with active trading around a recalibrated valuation band.
Latest quarter modestly ahead of expectations
In parallel with the stock’s pullback, Intuitive Surgical’s most recent quarterly performance has continued to show healthy underlying demand for robotic-assisted surgery, with a recent institutional strategy commentary highlighting that the company’s quarterly results were modestly ahead of consensus expectations.
That same commentary reports da Vinci procedure growth of 16 percent in the latest quarter, a key operational figure that underscores continued expansion in utilization across hospitals and surgical specialties.
For a mature medtech franchise, double-digit procedure growth of 16 percent in a single quarter is a meaningful data point, suggesting that hospitals are still investing in and using da Vinci systems at a robust pace despite macroeconomic uncertainties and evolving competitive dynamics.
The strategy note also indicates that Intuitive Surgical carried an average portfolio weight of 2.64 percent in the referenced large-cap sustainable growth strategy, with a total portfolio return contribution of -0.40 percent driven by a stock return of -13.74 percent over the period, illustrating how share-price weakness has weighed on institutional performance even as the fundamental story remains intact.
For investors, the combination of 16 percent procedure growth and modest beats versus consensus in the latest quarter, set against a more than 30 percent year-to-date share-price decline, raises questions about whether the market is re-rating the stock purely on competitive and valuation concerns or also anticipating a slowdown in future growth.
Importantly, the freshness of these quarterly figures keeps them within the standard recency window for fundamentals as of August 18, 2026, making them a relevant basis for assessing the state of Intuitive Surgical’s operations and demand trends.
Within the same commentary, the broader medtech and devices sector is noted as having experienced a sell-off, which has affected valuation multiples across the space and cut Intuitive Surgical’s forward price-to-earnings multiple roughly in half since late January 2026.
This compression in the forward P/E metric, combined with the stock’s 31.1 percent price decline since the start of 2026, frames a narrative in which investors are demanding a lower valuation for a still-growing franchise in light of potential competitive threats and sector-wide risk repricing.
New cardiac indications expand da Vinci 5 opportunity
Beyond quarterly demand metrics, a key recent development for Intuitive Surgical has been fresh regulatory clearance expanding the use of its newest platform, da Vinci 5, in cardiac surgery.
According to a detailed product and regulatory update, Intuitive Surgical has received FDA clearance for several cardiac procedures on the da Vinci 5 system using non-force feedback instruments, opening up a new category of robot-assisted interventions in cardiology.
The same analysis notes that in 2025, 17,000 cardiac procedures were performed globally using earlier da Vinci systems such as Si and Xi, giving a concrete baseline for existing robotic cardiac usage.
Intuitive Surgical’s own estimates cited in the update suggest an immediate opportunity of 160,000 cardiac procedures per year in markets where da Vinci 5 is cleared, including the United States and South Korea, implying a potential expansion by a factor of more than nine times versus 2025 observed volumes.
This quantified comparison - 17,000 cardiac procedures in 2025 versus an estimated 160,000 annual opportunity in cleared markets for da Vinci 5 - highlights how the new indications may substantially broaden the company’s total addressable market in a high-value specialty.
The regulatory clearance for cardiac procedures complements existing indications for urologic, gynecologic, general laparoscopic, thoracoscopic, and select trans-oral otolaryngology surgeries, reinforcing da Vinci’s multi-specialty positioning.
An updated product page for Intuitive Surgical’s stapling solutions underscores that da Vinci 5 and legacy systems such as da Vinci X and da Vinci Xi are intended to assist in accurate control of endoscopic instruments across these surgical domains for both adult and pediatric patients, except for certain restricted trans-oral procedures.
For hospital decision-makers, the expanded cardiac indications add a new dimension to the economic case for investing in da Vinci 5 systems, since one platform can support a wide range of procedures from urology and gynecology to thoracic and now selected cardiac operations.
From an investor perspective, the FDA’s clearance and the quantified 160,000-procedure annual opportunity feed directly into long-term growth expectations, though realization of that opportunity will depend on clinical adoption, reimbursement, and competition from other robotic systems entering the cardiac space.
Analyst expectations and earnings outlook
Alongside operational and regulatory developments, current consensus data point to ongoing earnings expansion for Intuitive Surgical over the medium term.
A recent earnings overview cites a consensus estimate for Intuitive Surgical’s 2026 earnings that implies a 12.7 percent increase from the prior-year level, suggesting that analysts expect double-digit profit growth even after factoring in recent valuation compression and competitive concerns.
The same consensus snapshot notes that Intuitive Surgical shares have gained 12.9 percent over the past six months, compared with a 3.2 percent decline for the referenced medtech industry group, indicating that the stock has outperformed peers over the half-year period despite being down more than 30 percent for full-year 2026.
This six-month outperformance versus the industry reflects a nuanced view from the market: while the stock has corrected sharply from earlier highs, investors still appear to assign a relative premium to Intuitive Surgical’s growth and competitive position compared with other device makers.
For investors, the 12.7 percent implied earnings growth for 2026, combined with continued double-digit procedure growth and fresh cardiac indications for da Vinci 5, paints a picture in which fundamentals remain solid even as the stock’s valuation and sentiment have swung more widely.
At the same time, the reduction in Intuitive Surgical’s forward P/E multiple to roughly half its late-January 2026 level shows that the market is applying a more conservative lens to future growth, potentially driven by concerns over emerging rivals in soft tissue robotics and instrumentation.
In addition to earnings expectations, a recent filings overview highlights ongoing insider and institutional activity, noting that the most recent SEC Form 4 related to Intuitive Surgical was submitted on August 12, 2026.
Regular filings such as Form 4 submissions track insider transactions, which investors often watch for signals around management’s confidence in the company’s prospects, though individual trades need to be interpreted carefully in context.
Valuation reset and long-term narrative
Commentary on Intuitive Surgical’s 2026 share-price performance stresses that the stock has plunged 33 percent so far in 2026, a figure consistent with the 31.1 percent decline measured from the beginning of the year to mid-August trading levels.
The use of the term “plunged” in this analysis underscores the severity of the correction, especially when contrasted with the company’s historical annual return profile of 17 percent gains on average over the prior decade.
The resulting market value, which is now anchored around the high-$390 price zone, is described as “quite a bit higher” than at the earliest 2026 troughs but nonetheless substantially below the earlier peak levels, reflecting a re-rating that may have cooled enthusiasm without fully erasing the franchise’s long-term premium.
In framing this move, the same analysis points to shifting sentiment around medtech and devices and the arrival of new robotic competitors as key drivers, factors that have led investors to question how much Intuitive Surgical can continue to dominate soft tissue robotics.
For long-term holders, the quantified picture matters: a stock that has delivered 17 percent average yearly gains over a decade but is down roughly one-third in the current year presents both risk and opportunity, depending on one’s view of whether recent competitive and regulatory developments strengthen or weaken the company’s moat.
Additional quantitative context from a valuation-focused blog shows Intuitive Surgical closing August 14, 2026 at $394.51, with a mid target price of $624 and a consensus street target around $478, figures that imply upside potential from current levels but also reflect a wide range of expectations around execution and competition.
The same analysis notes that the stock is around 20 percent above its 52-week low of $328.57 but still far below the mid target, emphasizing that while some recovery has taken place from the lowest 2026 prices, the path back to prior highs remains long.
For investors evaluating entry or re-entry, this combination of a compressed forward P/E, a 31.1 percent year-to-date price decline, and an implied mid target well above current levels raises practical questions about whether the market is over-discounting competitive risk or appropriately resetting expectations.
Ultimately, the valuation reset in 2026 has shifted Intuitive Surgical from the realm of a steadily compounding high-multiple medtech name to a more debated story where execution in new indications such as cardiac surgery and continued double-digit procedure growth will need to prove that the franchise can justify any recovery in its multiple.
da Vinci 5 and stapling as a flagship product suite
A central pillar of Intuitive Surgical’s business model is the da Vinci family of robotic systems, which integrate robotic arms, high-definition visualization, and specialized instruments to enable minimally invasive surgery across multiple specialties.
Within this portfolio, da Vinci 5 represents the latest generation platform, designed to assist surgeons in accurate control of endoscopes and instruments during urologic, gynecologic, general laparoscopic, thoracoscopic, and now selected cardiac procedures.
Accompanying the core system is a suite of stapling solutions marketed under the SureForm name, which are highlighted in product materials as key tools for tissue management and transection during complex procedures.
Intuitive Surgical’s product documentation emphasizes that the da Vinci X and da Vinci Xi systems, along with da Vinci 5, are intended for adult and pediatric use across their indicated surgical domains, with trans-oral otolaryngology procedures restricted to benign tumors and malignant tumors classified as T1 and T2, as well as benign base of tongue resection procedures.
These detailed indications underscore the breadth of the clinical footprint Intuitive Surgical has built over time, expanding from initial use in urology and gynecology to a broad array of general surgery and thoracic operations, and now to cardiac procedures on da Vinci 5.
From a business perspective, the da Vinci platform drives revenue across capital equipment sales, instrument and accessory utilization, and service contracts, creating a recurring revenue base tied to procedure volumes.
The addition of new indications such as cardiac surgery and continuous improvement in instrument sets like stapling expands both the total addressable market and the revenue per procedure opportunity, reinforcing the strategic importance of product innovation.
Stock level and trading venue
Intuitive Surgical stock trades on the Nasdaq under the ticker ISRG, denominated in USD, with recent market data showing a closing price of $390.33 on August 17, 2026.
As of that date, the shares had declined 31.1 percent year to date from $566.36 at the beginning of 2026, but remained around 20 percent above a 52-week low of $328.57, reflecting both substantial drawdown and partial recovery.
For investors tracking the name, this $390.33 closing level as of August 17, 2026 offers a concrete reference point for valuation discussions, sitting well below consensus target prices cited in recent analyses while anchoring the recalibrated trading range for the company’s shares.
Read more
MarketBeat overview of Intuitive Surgical stock
Da Vinci 5 in cardiac and multi-specialty surgery
Intuitive Surgical’s da Vinci 5 platform is engineered to support surgeons in performing minimally invasive procedures across multiple specialties, including recently cleared cardiac operations.
Product documentation describes how the system’s endoscopic instrument control enables precise movements in urologic, gynecologic, general laparoscopic, thoracoscopic, and select trans-oral otolaryngology procedures, with the new cardiac indications for da Vinci 5 adding to this multi-specialty reach.
Stapling solutions branded as SureForm complement the core system, providing tools for tissue management that are integrated with the robotic platform to support complex resections and reconstructions.
Intuitive Surgical stock level as of August 17, 2026
As of August 17, 2026, at 4:00 p.m. ET, Intuitive Surgical stock closed at $390.33 on the Nasdaq, marking a 31.1 percent decline from the $566.36 level at the beginning of 2026 but still trading around 20 percent above the 52-week low of $328.57 cited in recent performance analyses.
Fact box
Company: Intuitive Surgical Inc.
ISIN: US46120E6023
Ticker: ISRG
Exchange: Nasdaq
Price (as of August 17, 2026, 4:00 p.m. ET): $390.33 USD
Sector / Industry: Health care / Medical devices
Index membership: Nasdaq-100
